A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease
Authors
Nicolas R. Barthélemy
Yan Li
Nelly Joseph-Mathurin
Brian A. Gordon
Jason Hassenstab
Tammie L.S. Benzinger
Virginia Buckles
Anne M. Fagan
Richard J. Perrin
Alison M. Goate
John C. Morris
Celeste M. Karch
Chengjie Xiong
Ricardo Allegri
Patricio Chrem Mendez
Sarah B. Berman
Takeshi Ikeuchi
Hiroshi Mori
Hiroyuki Shimada
Mikio Shoji
Kazushi Suzuki
James Noble
Martin Farlow
Jasmeer Chhatwal
Neill R. Graff-Radford
Stephen Salloway
Peter R. Schofield
Colin L. Masters
Ralph N. Martins, Edith Cowan UniversityFollow
Antoinette O'Connor
Nick C. Fox
Johannes Levin
Mathias Jucker
Sylvain Lehmann
Chihiro Sato
Randall J. Bateman
Eric McDade
Dominantly Inherited Alzheimer Network
Document Type
Journal Article
Publication Title
Nature Medicine
Publisher
Nature Research
School
Centre for Exercise and Sports Science Research
RAS ID
31413
Funders
National Institute on Aging
Deutsches Zentrum Neurodegenerative Erkrankungen
Japan Agency for Medical Research and Development
Fondation Plan Alzheimer
Korea Health Industry Development Institute
Medical Research Council
National Institute of Neurological Disorders and Stroke
Abstract
Development of tau-based therapies for Alzheimer’s disease requires an understanding of the timing of disease-related changes in tau. We quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across four decades of disease progression in dominantly inherited Alzheimer’s disease. We identified a pattern of tau staging where site-specific phosphorylation changes occur at different periods of disease progression and follow distinct trajectories over time. These tau phosphorylation state changes are uniquely associated with structural, metabolic, neurodegenerative and clinical markers of disease, and some (p-tau217 and p-tau181) begin with the initial increases in aggregate amyloid-β as early as two decades before the development of aggregated tau pathology. Others (p-tau205 and t-tau) increase with atrophy and hypometabolism closer to symptom onset. These findings provide insights into the pathways linking tau, amyloid-β and neurodegeneration, and may facilitate clinical trials of tau-based treatments. © 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.
DOI
10.1038/s41591-020-0781-z
Access Rights
subscription content
Comments
Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L., ... & Morris, J. C. (2020). A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nature Medicine, 26(3), 398-407. https://doi.org/10.1038/s41591-020-0781-z